Ardsley Advisory Partners’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
Other funds holding AZN
Ardsley Advisory Partners's AZN Position: Q3 2026 in Review
Ardsley Advisory Partners opened a new position in AstraZeneca (AZN) in Q3 2026: 60,000 shares worth $9.7M. The stake represents 1.03% of the portfolio and ranks #33 among its holdings. This is a return to the name: Ardsley Advisory Partners previously reported a position in AZN as recently as Q3 2022.
Ardsley Advisory Partners first reported a position in AZN in Q4 2019 and has held it in 10 quarters since. The position peaked at $18.1M in Q3 2021. 1,446 funds tracked by Wall St. Rank hold AZN as of Q3 2026.
- Ardsley Advisory Partners held 60,000 shares of AstraZeneca worth $9.7M as of Q3 2026.
- AstraZeneca was a new Ardsley Advisory Partners position in Q3 2026.
- AstraZeneca made up 1.03% of Ardsley Advisory Partners's portfolio in Q3 2026, its #33 holding.
- Ardsley Advisory Partners first reported a position in AstraZeneca in Q4 2019 and has held it in 10 quarters since.
- Ardsley Advisory Partners's AstraZeneca position peaked at $18.1M in Q3 2021.
- 1,446 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.
Based on Ardsley Advisory Partners's 13F filing for Q3 2026, filed 16 Nov 2026.